Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis

Journal of Gastroenterology and Hepatology (Australia)

Volumn 24, Issue 11, 2009, Pages 1791-1797

  Narahara, Yoshiyuki ^a   Kanazawa, Hidenori ^a   Taki, Yasuhiko ^a   Kimura, Yuu ^a   Atsukawa, Masanori ^a   Katakura, Tamaki ^a   Kidokoro, Hideko ^a   Harimoto, Hirotomo ^a   Fukuda, Takeshi ^a   Matsushita, Yoko ^a   Nakatsuka, Katsuhisa ^a   Sakamoto, Choitsu ^a  

^a NIPPON MEDICAL SCHOOL   (Japan)

Author keywords

Cirrhosis; Hepatic arterial resistance; Renal arterial resistance; Terlipressin

Indexed keywords

NEUROHORMONE; TERLIPRESSIN;

ADULT; AGED; ARTERY RESISTANCE; ARTICLE; ASCITES; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART OUTPUT; HEART RATE; HEPATIC ARTERY; HUMAN; KIDNEY BLOOD FLOW; LIVER BLOOD FLOW; LIVER CIRRHOSIS; MALE; MEAN ARTERIAL PRESSURE; PLASMA RENIN ACTIVITY; PORTAL HYPERTENSION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RENAL ARTERY; SYSTEMIC VASCULAR RESISTANCE; VEIN BLOOD FLOW; VENOUS PRESSURE;

EID: 70449433111     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2009.05873.x     Document Type: Article

References (30)

1. Ioannou GN, Doust J, Rockey DC. Systematic review: terlipressin in acute oesophageal variceal haemorrhage. Aliment. Pharmacol. Ther. 2003 17 : 53 64.
2. Neri S, Pulvirenti D, Malaguarnera M et al. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. Dig. Dis. Sci. 2008 53 : 830 835.
3. Solanki P, Chawla A, Garg R, Gupta R, Jain M, Sarin SK. Beneficial effects of terlipressin in hepatorenal syndrome: a prospective, randomized placebo-controlled clinical trial. J. Gastroenterol. Hepatol. 2003 18 : 152 156.
4. Moreau R, Durand F, Poynard T et al. Terlipressin in patients with cirrhosis and type 1 hepatorenal syndrome: a retrospective multicenter study. Gastroenterology 2002 122 : 923 930. (Pubitemid 34267275)
5. Halimi C, Bonnard P, Bernard B et al. Effect of terlipressin (Glypressin) on hepatorenal syndrome in cirrhotic patients: results of a multicentre pilot study. Eur. J. Gastroenterol. Hepatol. 2002 14 : 153 158.
6. Ortega R, Gines P, Uriz J et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002 36 : 941 948.
7. Uriz J, Gines P, Cardenas A et al. Terlipressin plus albumin infusion: an effective and safe therapy of hepatorenal syndrome. J. Hepatol. 2000 33 : 43 8.
8. Møller S, Hansen EF, Becker U, Brinch K, Henriksen JH, Bendtsen F. Central and systemic haemodynamic effects of terlipressin in portal hypertensive patients. Liver 2000 20 : 51 9.
9. Merkel C, Gatta A, Bolognesi M et al. Hemodynamic changes of systemic, hepatic, and splenic circulation following triglycyl-lysin-vasopressin administration in alcoholic cirrhosis. Dig. Dis. Sci. 1988 33 : 1103 1109.
10. Gadano A, Moreau R, Vachiery F et al. Natriuretic response to the combination of atrial natriuretic peptide and terlipressin in patients with cirrhosis and refractory ascites. J. Hepatol. 1997 26 : 1229 1234.
11. Escorsell A, Bandi JC, Moitinho E et al. Time profile of the haemodynamic effects of terlipressin in portal hypertension. J. Hepatol. 1997 26 : 621 627.
12. Baik SK, Jeong PH, Ji SW et al. Acute hemodynamic effects of octreotide and terlipressin in patients with cirrhosis: a randomized comparison. Am. J. Gastroenterol. 2005 100 : 631 635.
13. Colli A, Cocciolo M, Mumoli N, Cattalini N, Fraquelli M, Conte D. Hepatic artery resistance in alcoholic liver disease. Hepatology 1998 28 : 1182 1186.
14. Sacerdoti D, Bolognesi M, Merkel C, Angeli P, Gatta A. Renal vasoconstriction in cirrhosis evaluated by duplex Doppler ultrasonography. Hepatology 1993 17 : 219 224.
15. Iwao T, Toyonaga A, Shigemori H et al. Hepatic artery hemodynamic responsiveness to altered portal blood flow in normal and cirrhotic livers. Radiology 1996 200 : 793 798.
16. Kam PC, Williams S, Yoong FF. Vasopressin and terlipressin: pharmacology and its clinical relevance. Anaesthesia 2004 59 : 993 1001.
17. Nilsson G, Lindblom P, Ohlin M, Berling R, Vernersson E. Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp. Clin. Res. 1990 16 : 307 314.
18. Hansen EF, Strandberg C, Hojgaard L et al. Splanchnic haemodynamics after intravenous terlipressin in anaesthetised healthy pigs. J. Hepatol. 1999 30 : 503 510.
19. Guevara M, Gines P. Hepatorenal syndrome. Dig. Dis. 2005 23 : 47 55. (Pubitemid 40827662)
20. Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Gut 2008 57 : 268 278.
21. Schrier RW, Arroyo V, Bernardi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988 8 : 1151 1157.
22. Kiszka-Kanowitz M, Henriksen JH, Møller S, Bendtsen F. Blood volume distribution in patients with cirrhosis: aspects of the dual-head gamma-camera technique. J. Hepatol. 2001 35 : 605 612.
23. Henriksen JH, Bendtsen F, Sørensen TIA, Stadeager C, Ring-Larsen H. Reduced central blood volume in cirrhosis. Gastroenterology 1989 97 : 1506 1513.
24. Hirasawa A, Shibata K, Kotosai K, Tsujimoto G. Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor. Biochem. Biophys. Res. Commun. 1994 203 : 72 9.
25. Lenz K, Hörtnagl H, Druml W et al. Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Gastroenterology 1991 101 : 1060 1067.
26. Richter S, Mücke I, Menger MD, Vollmar B. Impact of intrinsic blood flow regulation in cirrhosis: maintenance of hepatic arterial buffer response. Am. J. Physiol. Gastrointest. Liver Physiol. 2000 279 : G454 62.
27. Lautt WW, Legare DJ, Ezzat WR. Quantitation of the hepatic arterial buffer response to graded changes in portal blood flow. Gastroenterology 1990 98 : 1024 1028.
28. Gülberg V, Haag K, Rössle M, Gerbes AL. Hepatic arterial buffer response in patients with advanced cirrhosis. Hepatology 2002 35 : 630 634.
29. Kleber G, Steudel N, Behrmann C et al. Hepatic arterial flow volume and reserve in patients with cirrhosis: use of intra-arterial Doppler and adenosine infusion. Gastroenterology 1999 116 : 906 914.
30. Lee SS, Chilton EL, Pak JM. Adenosine receptor blockade reduces splanchnic hyperemia in cirrhotic rats. Hepatology 1992 15 : 1107 1111.